Recent News

• 06.30.2025 - Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
• 06.27.2025 - Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
• 06.26.2025 - Achieve Life Sciences Announces Proposed Underwritten Public Offering
• 06.26.2025 - Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
• 06.26.2025 - Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
• 05.28.2025 - Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
• 05.20.2025 - Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake
• 05.13.2025 - Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

Recent Filings

• 06.27.2025 - 8-K Current report
• 06.27.2025 - EX-99.1 EX-99.1
• 06.27.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.26.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities